Silo Pharma, Inc. (SILO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on novel therapeutics for PTSD, anxiety, fibromyalgia, and CNS diseases. The company recently announced a strategic pivot to include a cryptocurrency treasury strategy (August 2025) focused on acquiring digital assets like Bitcoin, Ethereum, and Solana. The company is classified as a smaller reporting company and non-accelerated filer.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value |
|---|---|
| Revenue | $36,051 |
| Net Loss | $(2,235,730) |
| Net Loss Per Share (Basic/Diluted) | $(0.41) |
| Cash and Cash Equivalents | $4,333,672 |
| Short-Term Investments | $1,926,297 |
| Working Capital | $5,323,134 |
| Accumulated Deficit | $(17,500,421) |
| Operating Cash Flow | $(2,925,568) |
| Financing Cash Flow | $2,093,958 |
Material Changes vs. Prior Period
- Revenue: Remained flat at $36,051 for the six months ended June 30, 2025, compared to the same period in 2024. Revenue is derived entirely from license fee amortization related to the Aikido Pharma agreement.
- Net Loss: Increased by 29.0% to $(2.24) million from $(1.73) million in the prior year period, driven primarily by higher operating expenses.
- Operating Expenses: Increased by 24.0% to $2.38 million.
- R&D Expenses: Rose 69.2% to $1.31 million due to increased costs for Investigator-sponsored Study Agreements and third-party vendors.
- Compensation: Increased 9.4% to $373,774, largely due to $17,445 in stock-based compensation from new option grants.
- Professional Fees: Decreased 10.6% to $573,416, driven by lower consulting and investor relations costs.
- Liquidity: Cash and cash equivalents increased by $427,873 to $4.33 million, supported by financing activities. Short-term investments decreased by $1.25 million as the company sold assets to fund operations.
- Capital Structure: The company completed a public offering in May 2025, raising net proceeds of approximately $1.59 million. Outstanding common shares increased from 4.48 million (Dec 2024) to 8.65 million (June 2025) due to the offering and warrant exercises.
Guidance, Outlook, and Risks
- Strategic Pivot: Management announced a new cryptocurrency treasury strategy in August 2025, establishing a Crypto Advisory Board. This introduces significant new risks related to digital asset volatility, regulatory classification (potential "security" status), and cybersecurity.
- Product Pipeline:
- SPC-15: Lead candidate for PTSD/anxiety; pre-IND meeting held with FDA in Sept 2024; aiming for IND submission in 2025.
- SP-26: Ketamine implant for fibromyalgia; in preclinical research.
- SPU-16: CNS-homing peptide for Multiple Sclerosis. The Master License Agreement with the University of Maryland, Baltimore (UMB) was terminated in July 2025 and replaced with an option agreement expiring March 31, 2026.
- Liquidity Outlook: Management believes current cash and short-term investments are sufficient to meet obligations for at least 12 months. However, the company has an accumulated deficit of $17.5 million and continues to burn cash on operations.
- Listing Compliance: The company received a Nasdaq deficiency notice on June 27, 2025, regarding the minimum bid price requirement ($1.00). It has 180 days (until Dec 24, 2025) to regain compliance, potentially via a reverse stock split.
- Risks: Key risks include the ability to obtain additional funding, clinical trial outcomes, intellectual property disputes, and the regulatory uncertainty surrounding the new cryptocurrency strategy.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $2.9M operating cash burn over the next 12 months given the new crypto strategy costs.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement by December 2025 to avoid delisting.
- License Status: Confirm the status of the new option agreement with UMB regarding SPU-16 and the potential impact on the pipeline if the option is not exercised.
- Crypto Strategy Execution: Review the specific allocation of capital to digital assets and the custody arrangements to assess security and regulatory risks.
- Dilution: Assess the impact of the 8.3M warrants outstanding (weighted average exercise price $1.66) on future share count and earnings per share.